Literature DB >> 15016718

Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH.

Johanna G Miquet1, Ana I Sotelo, Andrzej Bartke, Daniel Turyn.   

Abstract

High continuous GH levels in vivo produce desensitization of the Janus tyrosine kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) pathway of GH signaling in the liver. To evaluate the mechanisms involved in this desensitization, transgenic mice overexpressing bovine GH were used. In these animals, GH receptor and membrane-associated JAK2 kinase are increased 4.5- and 6-fold, respectively. However, JAK2. STAT5a and -5b do not become tyrosine phosphorylated in response to GH stimulus, nor are these STAT proteins recruited to membranes, suggesting that they cannot bind to the receptor. The content of the suppressor cytokine-inducible src homology 2 (SH2)-containing protein (CIS), both total and membrane-associated, is markedly increased in the liver of GH transgenic mice. This could account for the inhibition of STAT5 activation, because CIS competes with STAT5 for GH receptor docking sites. Existence of an alternative mechanism of negative regulation of this signaling pathway by chronically elevated GH levels is suggested by the low level of JAK2 phosphorylation that transgenic mice exhibit. Whereas total SH2-containing phosphatase 2 (SHP-2) content is the same in both kinds of mice, membrane-associated SHP-2 protein levels increase 4.5-fold in GH transgenic animals. This could explain the dramatic inhibition of JAK2 phosphotyrosine level, thus contributing to the suppression of GH signaling observed in these transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016718     DOI: 10.1210/en.2003-1498

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver.

Authors:  Ma Eugenia Díaz; Lorena González; Johanna G Miquet; Carolina S Martínez; Ana I Sotelo; Andrzej Bartke; Daniel Turyn
Journal:  Cell Signal       Date:  2011-10-14       Impact factor: 4.315

2.  Food intake and appetite control in a GH-transgenic zebrafish.

Authors:  Camila Dalmolin; Daniela Volcan Almeida; Marcio Azevedo Figueiredo; Luis Fernando Marins
Journal:  Fish Physiol Biochem       Date:  2015-05-20       Impact factor: 2.794

3.  Regulation of cytokine-inducible SH2-containing protein (CIS) by ubiquitination and Elongin B/C interaction.

Authors:  Philip J Jensik; Lydia A Arbogast
Journal:  Mol Cell Endocrinol       Date:  2014-11-04       Impact factor: 4.102

4.  GH/STAT5 signaling during the growth period in livers of mice overexpressing GH.

Authors:  Carolina S Martinez; Verónica G Piazza; María E Díaz; Ravneet K Boparai; Oge Arum; María C Ramírez; Lorena González; Damasia Becú-Villalobos; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  J Mol Endocrinol       Date:  2015-02-17       Impact factor: 5.098

5.  Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Authors:  Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

6.  Mitogenic signaling pathways in the liver of growth hormone (GH)-overexpressing mice during the growth period.

Authors:  Carolina S Martinez; Verónica G Piazza; Lorena González; Yimin Fang; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  GH modulates hepatic epidermal growth factor signaling in the mouse.

Authors:  Lorena González; Ma Eugenia Díaz; Johanna G Miquet; Ana I Sotelo; Diego Fernández; Fernando P Dominici; Andrzej Bartke; Daniel Turyn
Journal:  J Endocrinol       Date:  2009-12-23       Impact factor: 4.286

8.  Resistance to the Beneficial Metabolic Effects and Hepatic Antioxidant Defense Actions of Fibroblast Growth Factor 21 Treatment in Growth Hormone-Overexpressing Transgenic Mice.

Authors:  Ravneet K Boparai; Oge Arum; Johanna G Miquet; Michal M Masternak; Andrzej Bartke; Romesh K Khardori
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.